{"url":"https://lda.senate.gov/api/v1/filings/551cb098-e8b9-4e86-bc01-020c8be98fc8/","filing_uuid":"551cb098-e8b9-4e86-bc01-020c8be98fc8","filing_type":"RR","filing_type_display":"Registration","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/551cb098-e8b9-4e86-bc01-020c8be98fc8/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Lauren Henderson","dt_posted":"2025-03-14T10:00:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"121 Reynolda Village Way Ste. A","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"Winston Salem","registrant_state":"NC","registrant_zip":"27106","registrant":{"id":401109039,"url":"https://lda.senate.gov/api/v1/registrants/401109039/","house_registrant_id":56739,"name":"CHECKMATE GOVERNMENT RELATIONS","description":null,"address_1":"121 Reynolda Village Way Ste. A","address_2":null,"address_3":null,"address_4":null,"city":"Winston Salem","state":"NC","state_display":"North Carolina","zip":"27106","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KENDALL CONGER","contact_telephone":"+1 919-740-1863","dt_updated":"2026-02-23T15:42:24.929627-05:00"},"client":{"id":64838,"url":"https://lda.senate.gov/api/v1/clients/64838/","client_id":64838,"name":"GSK","general_description":"Pharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-03-03"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Focused engagement with HHS regarding pharmaceutical technology.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":148520,"prefix":null,"prefix_display":null,"first_name":"FREDERICK","nickname":null,"middle_name":null,"last_name":"VAUGHAN","suffix":null,"suffix_display":null},"covered_position":"Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House","new":true},{"lobbyist":{"id":148771,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"MCDOWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Focused engagement with HHS regarding pharmaceutical technology.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":148520,"prefix":null,"prefix_display":null,"first_name":"FREDERICK","nickname":null,"middle_name":null,"last_name":"VAUGHAN","suffix":null,"suffix_display":null},"covered_position":"Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House","new":true},{"lobbyist":{"id":148771,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"MCDOWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}